Published in J Hepatol on August 25, 2005
Herbal medicine in the United States: review of efficacy, safety, and regulation: grand rounds at University of California, San Francisco Medical Center. J Gen Intern Med (2008) 2.08
Hydroxycut hepatotoxicity: a case series and review of liver toxicity from herbal weight loss supplements. World J Gastroenterol (2008) 1.75
Acute hepatitis associated with the use of green tea infusions. J Hepatol (2005) 1.52
Drug-Induced Liver Injury: Twenty Five Cases of Acute Hepatitis Following Ingestion of Polygonum multiflorum Thunb. Gut Liver (2011) 1.19
Acute liver failure caused by 'fat burners' and dietary supplements: a case report and literature review. Can J Gastroenterol (2011) 1.08
Acute liver injury associated with the use of herbal preparations containing glucosamine: three case studies. BMJ Case Rep (2009) 1.05
Liver enzyme abnormalities in systemic lupus erythematosus: a focus on toxic hepatitis. Rheumatol Int (2009) 1.00
Serious adverse liver reactions associated with herbal weight-loss supplements. J Hepatol (2007) 0.98
Hepatotoxicity due to extracts of Chinese green tea (Camellia sinensis): a growing concern. J Hepatol (2006) 0.97
Green tea polyphenols supplementation and Tai Chi exercise for postmenopausal osteopenic women: safety and quality of life report. BMC Complement Altern Med (2010) 0.97
Chinese medicines as a resource for liver fibrosis treatment. Chin Med (2009) 0.94
Effects of long-term silymarin oral supplementation on the blood biochemical profile of rainbow trout (Oncorhynchus mykiss). Fish Physiol Biochem (2011) 0.91
Reactivation of Pulmonary Tuberculosis in a Patient with Polygonum multiflorum Thunb-Induced Hepatitis. Gut Liver (2009) 0.88
Aloe-induced toxic hepatitis. J Korean Med Sci (2010) 0.87
Herbal products: benefits, limits, and applications in chronic liver disease. Evid Based Complement Alternat Med (2012) 0.86
Inflammatory stress potentiates emodin-induced liver injury in rats. Front Pharmacol (2015) 0.81
Optimal management for alcoholic liver disease: Conventional medications, natural therapy or combination? World J Gastroenterol (2016) 0.80
Hepatotoxicity associated with the dietary supplement OxyELITE Pro™ - Hawaii, 2013. Drug Test Anal (2015) 0.79
Drug-induced liver injury associated with Complementary and Alternative Medicine: a review of adverse event reports in an Asian community from 2009 to 2014. BMC Complement Altern Med (2016) 0.79
Drug-induced Liver Injury. US Gastroenterol Hepatol Rev (2010) 0.76
Herbal Remedies for Functional Dyspepsia and Traditional Iranian Medicine Perspective. Iran Red Crescent Med J (2015) 0.75
Murrah and Sunn herbs induced liver failure. Ann Saudi Med (2010) 0.75
Tea not Tincture: Hepatotoxicity Associated with Rooibos Herbal Tea. ACG Case Rep J (2013) 0.75
A synergistic effect of Cremophor and beta glucosylceramide to exert liver and sugar protection. J Food Sci Technol (2017) 0.75
Hepatotoxic potential of asarones: in vitro evaluation of hepatotoxicity and quantitative determination in herbal products. Front Pharmacol (2015) 0.75
Complementary and alternative medicines for hepatic disease. Gastroenterol Hepatol (N Y) (2008) 0.75
Liver injury after aluminum potassium sulfate and tannic acid treatment of hemorrhoids. World J Gastroenterol (2017) 0.75
Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology (2004) 6.14
IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology (2010) 3.57
Hedgehog signaling regulates epithelial-mesenchymal transition during biliary fibrosis in rodents and humans. J Clin Invest (2008) 2.89
Wheat amylase trypsin inhibitors drive intestinal inflammation via activation of toll-like receptor 4. J Exp Med (2012) 2.58
Targeting liver fibrosis: strategies for development and validation of antifibrotic therapies. Hepatology (2009) 2.16
Severe hepatotoxicity following ingestion of Herbalife nutritional supplements contaminated with Bacillus subtilis. J Hepatol (2008) 2.07
Update on serologic testing in celiac disease. Am J Gastroenterol (2010) 2.07
The incidence and clinical spectrum of refractory celiac disease in a north american referral center. Am J Gastroenterol (2011) 1.96
Tissue transglutaminase does not affect fibrotic matrix stability or regression of liver fibrosis in mice. Gastroenterology (2011) 1.85
Etiologies and predictors of diagnosis in nonresponsive celiac disease. Clin Gastroenterol Hepatol (2007) 1.82
The clinical utility of biomarkers and the nonalcoholic steatohepatitis CRN liver biopsy scoring system in patients with nonalcoholic fatty liver disease. J Gastroenterol Hepatol (2009) 1.77
Non-Celiac Gluten sensitivity: the new frontier of gluten related disorders. Nutrients (2013) 1.74
Failure of fibrotic liver regeneration in mice is linked to a severe fibrogenic response driven by hepatic progenitor cell activation. Am J Pathol (2013) 1.73
Inhibition of integrin alphavbeta6 on cholangiocytes blocks transforming growth factor-beta activation and retards biliary fibrosis progression. Gastroenterology (2008) 1.69
Serum hyaluronate correlates with histological progression in alcoholic liver disease. Eur J Gastroenterol Hepatol (2003) 1.64
Mdr2 (Abcb4)-/- mice spontaneously develop severe biliary fibrosis via massive dysregulation of pro- and antifibrogenic genes. J Hepatol (2005) 1.62
Novel engineered targeted interferon-gamma blocks hepatic fibrogenesis in mice. Hepatology (2011) 1.61
Sublethal heat treatment promotes epithelial-mesenchymal transition and enhances the malignant potential of hepatocellular carcinoma. Hepatology (2013) 1.59
[Prevalence of circulating autoantibodies in healthy individuals]. Med Klin (Munich) (2002) 1.52
Mortality excess in individuals with elevated IgA anti-transglutaminase antibodies: the KORA/MONICA Augsburg cohort study 1989-1998. Eur J Epidemiol (2006) 1.51
Pathomechanisms in celiac disease. Int Arch Allergy Immunol (2003) 1.51
Serum connective tissue markers as predictors of advanced fibrosis in patients with chronic hepatitis B and D. Turk J Gastroenterol (2011) 1.48
Integrin alphavbeta6 is a marker of the progression of biliary and portal liver fibrosis and a novel target for antifibrotic therapies. J Hepatol (2008) 1.47
Endoscopic ultrasound-guided endoscopic necrosectomy of the pancreas: is irrigation necessary? Surg Endosc (2011) 1.46
Anti-tumor necrosis factor-alpha monoclonal antibody therapy in severe alcoholic hepatitis. J Hepatol (2003) 1.45
EUS-guided alcohol ablation of an insulinoma. Gastrointest Endosc (2006) 1.45
Elevated liver regeneration in response to pharmacological reduction of elevated portal venous pressure by terlipressin after partial hepatectomy. Transplantation (2014) 1.44
Celiac crisis is a rare but serious complication of celiac disease in adults. Clin Gastroenterol Hepatol (2010) 1.40
Halofuginone induces matrix metalloproteinases in rat hepatic stellate cells via activation of p38 and NFkappaB. J Biol Chem (2006) 1.40
Pharmacological inhibition of integrin alphavbeta3 aggravates experimental liver fibrosis and suppresses hepatic angiogenesis. Hepatology (2009) 1.39
Acupuncture and moxibustion in the treatment of ulcerative colitis: a randomized controlled study. Scand J Gastroenterol (2006) 1.38
Kinetics of the histological, serological and symptomatic responses to gluten challenge in adults with coeliac disease. Gut (2012) 1.37
Trichostatin A, a histone deacetylase inhibitor, suppresses collagen synthesis and prevents TGF-beta(1)-induced fibrogenesis in skin fibroblasts. Exp Cell Res (2002) 1.36
EGFR blockade by cetuximab alone or as combination therapy for growth control of hepatocellular cancer. Biochem Pharmacol (2005) 1.35
Comparison of transient elastography, serum markers and clinical signs for the diagnosis of compensated cirrhosis. J Gastroenterol Hepatol (2010) 1.33
Activation of tumor-specific T lymphocytes by radio-frequency ablation of the VX2 hepatoma in rabbits. Cancer Res (2003) 1.33
Growth factor receptors and related signalling pathways as targets for novel treatment strategies of hepatocellular cancer. World J Gastroenterol (2008) 1.31
World Gastroenterology Organisation global guidelines on celiac disease. J Clin Gastroenterol (2013) 1.29
Targeting the epidermal growth factor receptor by gefitinib for treatment of hepatocellular carcinoma. J Hepatol (2004) 1.28
Acupuncture and moxibustion in the treatment of active Crohn's disease: a randomized controlled study. Digestion (2004) 1.26
The histone-deacetylase inhibitor Trichostatin A blocks proliferation and triggers apoptotic programs in hepatoma cells. J Hepatol (2002) 1.25
A simple validated gluten-free diet adherence survey for adults with celiac disease. Clin Gastroenterol Hepatol (2009) 1.24
HIV and HCV cooperatively promote hepatic fibrogenesis via induction of reactive oxygen species and NFkappaB. J Biol Chem (2010) 1.24
Hepatitis C virus-replicating hepatocytes induce fibrogenic activation of hepatic stellate cells. Gastroenterology (2005) 1.24
Blockade of IGF-1 receptor tyrosine kinase has antineoplastic effects in hepatocellular carcinoma cells. Biochem Pharmacol (2006) 1.21
Human T cell microparticles circulate in blood of hepatitis patients and induce fibrolytic activation of hepatic stellate cells. Hepatology (2010) 1.20
Pathomechanisms in celiac disease. Best Pract Res Clin Gastroenterol (2005) 1.18
Progression of liver fibrosis in post-transplant hepatitis C: mechanisms, assessment and treatment. J Hepatol (2012) 1.18
Macrophage-mediated phagocytosis of apoptotic cholangiocytes contributes to reversal of experimental biliary fibrosis. Am J Physiol Gastrointest Liver Physiol (2010) 1.17
Keratin variants associate with progression of fibrosis during chronic hepatitis C infection. Hepatology (2006) 1.14
Effect of HMG-CoA reductase inhibitors on proliferation and protein synthesis by rat hepatic stellate cells. J Hepatol (2003) 1.14
Erlotinib induces cell cycle arrest and apoptosis in hepatocellular cancer cells and enhances chemosensitivity towards cytostatics. J Hepatol (2005) 1.13
Factors that influence adherence to a gluten-free diet in adults with celiac disease. Dig Dis Sci (2008) 1.12
Hepatocyte transplantation activates hepatic stellate cells with beneficial modulation of cell engraftment in the rat. Hepatology (2005) 1.12
Differential modulation of rat hepatic stellate phenotype by natural and synthetic retinoids. Hepatology (2004) 1.12
Mass-encoded synthetic biomarkers for multiplexed urinary monitoring of disease. Nat Biotechnol (2012) 1.10
The receptor for advanced glycation end products is highly expressed in the skin and upregulated by advanced glycation end products and tumor necrosis factor-alpha. J Invest Dermatol (2006) 1.09
Prediction of progression to cirrhosis by a glutathione S-transferase P1 polymorphism in subjects with hereditary hemochromatosis. Arch Intern Med (2005) 1.07
Circulating microparticles as disease-specific biomarkers of severity of inflammation in patients with hepatitis C or nonalcoholic steatohepatitis. Gastroenterology (2012) 1.06
Ethanol-induced cytochrome P4502E1 causes carcinogenic etheno-DNA lesions in alcoholic liver disease. Hepatology (2009) 1.05
Activation and dramatically increased cytolytic activity of tumor specific T lymphocytes after radio-frequency ablation in patients with hepatocellular carcinoma and colorectal liver metastases. World J Gastroenterol (2006) 1.04
Histone deacetylase inhibitor MS-275 alone or combined with bortezomib or sorafenib exhibits strong antiproliferative action in human cholangiocarcinoma cells. World J Gastroenterol (2007) 1.04
Sorafenib alone or as combination therapy for growth control of cholangiocarcinoma. Biochem Pharmacol (2007) 1.03
Pharmacological inhibition of the vitronectin receptor abrogates PDGF-BB-induced hepatic stellate cell migration and activation in vitro. J Hepatol (2006) 1.03
Disordered pancreatic inflammatory responses and inhibition of fibrosis in CD39-null mice. Gastroenterology (2007) 1.00
Discovery of a novel and rich source of gluten-degrading microbial enzymes in the oral cavity. PLoS One (2010) 1.00
Nonalcoholic steatohepatitis: the therapeutic challenge of a global epidemic. Curr Opin Lipidol (2011) 1.00
Alcohol dehydrogenase 1C*1 allele is a genetic marker for alcohol-associated cancer in heavy drinkers. Int J Cancer (2006) 0.99
A validated disease-specific symptom index for adults with celiac disease. Clin Gastroenterol Hepatol (2009) 0.99
Matrix metalloproteinase pattern in celiac duodenal mucosa. Lab Invest (2005) 0.97
Reciprocal modulation of matrix metalloproteinase-13 and type I collagen genes in rat hepatic stellate cells. Am J Pathol (2003) 0.96
A new model of interactive effects of alcohol and high-fat diet on hepatic fibrosis. Alcohol Clin Exp Res (2011) 0.96
Identification of Rothia bacteria as gluten-degrading natural colonizers of the upper gastro-intestinal tract. PLoS One (2011) 0.96
Antiproliferative and proapoptotic effects of histone deacetylase inhibitors on gastrointestinal neuroendocrine tumor cells. Endocr Relat Cancer (2006) 0.96
Broad-spectrum matrix metalloproteinase inhibition curbs inflammation and liver injury but aggravates experimental liver fibrosis in mice. PLoS One (2010) 0.96
Hepatotoxicity of alcohol-induced polar retinol metabolites involves apoptosis via loss of mitochondrial membrane potential. FASEB J (2005) 0.94
Precision-cut liver slices: a tool to model the liver ex vivo. J Hepatol (2013) 0.94
Hypoxia-inducible factor 1 alpha under rapid enzymatic hypoxia: cells sense decrements of oxygen but not hypoxia per se. Free Radic Biol Med (2008) 0.93
Hepatitis induced by Kava (Piper methysticum rhizoma). J Hepatol (2003) 0.93
Efficacy and tolerability of pegylated IFN-alpha in patients with neuroendocrine gastroenteropancreatic carcinomas. J Interferon Cytokine Res (2006) 0.92
In vitro differentiation of human monocytes into dendritic cells by peptic-tryptic digest of gliadin is independent of genetic predisposition and the presence of celiac disease. J Clin Immunol (2008) 0.91
Human intestinal fibroblasts prevent apoptosis in human intestinal mast cells by a mechanism independent of stem cell factor, IL-3, IL-4, and nerve growth factor. J Immunol (2004) 0.91
VEGF induces proliferation, migration, and TGF-beta1 expression in mouse glomerular endothelial cells via mitogen-activated protein kinase and phosphatidylinositol 3-kinase. Biochem Biophys Res Commun (2005) 0.90
Epithelial-to-mesenchymal transition in liver fibrosis: dead or alive? Gastroenterology (2010) 0.90
The histone-deacetylase inhibitor SAHA potentiates proapoptotic effects of 5-fluorouracil and irinotecan in hepatoma cells. J Cancer Res Clin Oncol (2005) 0.90
Matrix metalloproteinases in necrotising enterocolitis. Pediatr Res (2003) 0.90
Human risk allele HLA-DRB1*0405 predisposes class II transgenic Ab0 NOD mice to autoimmune pancreatitis. Gastroenterology (2010) 0.89
Serum laminin-2 and hyaluronan predict severe liver fibrosis in children with chronic hepatitis B. Hepatology (2004) 0.89
Targeted therapy of liver fibrosis/cirrhosis and its complications. J Hepatol (2011) 0.89
Interstitial collagens I, III, and VI sequester and modulate the multifunctional cytokine oncostatin M. J Biol Chem (2001) 0.88
Role of the receptor for advanced glycation end products in hepatic fibrosis. World J Gastroenterol (2009) 0.88
Liver-homing of purified glucose oxidase: a novel in vivo model of physiological hepatic oxidative stress (H2O2). J Hepatol (2006) 0.88